FULVESTRANT

Fulvestrant is an estrogen receptor antagonist used in hormonepositive breast cancer. Side effects include injectionsite pain, nausea, and fatigue. Only GMP materials will be supplied, logistics all according to GDP.

SKU: db4a0073d6a8 Category: Tag:

Product Description


Mechanism of Action

Fulvestrant is a selective estrogen receptor degrader (SERD) that binds ER, accelerates receptor degradation and blocks estrogenmediated transcription.

Benefits and Advantages

Used in endocrinetherapy models, ER degradation assays, breastcancer signalling research and SERD SAR analysis.

Side Effects and Risks

Injectionsite pain, hot flashes, nausea and hepatic changes.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C32H47F5O3S

Molecular Weight

606.8 g/mol

CAS Number

129453-61-8

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Fulvestrant; 129453-61-8; Faslodex; Ici 182780; ICI-182780

IUPAC/Chemical Name

(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol

InChl Key

VWUXBMIQPBEWFH-WCCTWKNTSA-N

InChl Code

InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/104741;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download